Market Cap 26.33B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 9.45
Forward PE 9.19
Profit Margin 32.42%
Debt to Equity Ratio 0.92
Volume 2,682,100
Avg Vol 3,720,274
Day's Range N/A - N/A
Shares Out 576.86M
Stochastic %K 24%
Beta 0.40
Analysts Strong Sell
Price Target $52.43

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
JuggernautRaider
JuggernautRaider Mar. 11 at 2:56 PM
$FBIO don’t be shocked if the sell the CUTX-101 royalty stream to $RPRX for a nice premium 🚀
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:34 PM
$RPRX Current Stock Price: $45.97 Contracts to trade: $45.0 RPRX Mar 20 2026 Call Entry: $1.20 Exit: $1.92 ROI: 60% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$RPRX Royalty Pharma Plc (NASDAQ: RPRX) is quietly becoming one of the most intriguing cheap biotech stocks as its royalty-based business model generates recurring revenue from blockbuster medicines. With analysts raising price targets and the company holding billions in financial firepower for new acquisitions, RPRX stock could offer investors exposure to biotech growth without the typical drug development risks. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-royalty-pharma-rprx-shares/
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 6 at 3:00 PM
$FBIO anyone else wondering if they’ll sell tbe CUTX-101 royalty stream to $RPRX ? 🧐
0 · Reply
TechridyStocks
TechridyStocks Mar. 6 at 1:39 AM
$RPRX still solid
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 2 at 1:39 PM
$RPRX (-7.2% pre) $ZYME (-3.3% pre) Ziihera cancer drug sparks $250M Royalty Pharma–Zymeworks deal https://ooc.bz/l/95120
0 · Reply
briefingcom
briefingcom Mar. 2 at 1:32 PM
$ZYME: Zymeworks & and Royalty Pharma $RPRX enter into $250 million royalty-backed note financing https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260302060706ZYME&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 12:15 PM
$RPRX Share Price: $46.22 Contract Selected: Oct 16, 2026 $52.5 Calls Buy Zone: $0.88 – $1.09 Target Zone: $1.55 – $1.90 Potential Upside: 67% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 11:10 AM
$RPRX Zymeworks Inc. (ZYME) announced a royalty-backed note financing of $250 million from Royalty Pharma plc (RPRX) with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid.…
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 28 at 2:05 AM
$SNDX SNDX did not record a "current portion of royalty financing agreement" on their 12/31/2025 Balance Sheet. The attachment summarizes the current & long-term obligations due RPRX as of the end of the last 5 quarters (per their Ks & Qs). The accounting for these royalty type agreements is complex. We are not CPAs but, generally speaking, the current portion represents amounts estimated due $RPRX over the following 12-months, allowing investors to determine SNDX calculated Niktimvo sales projections. SNDX, per their 10K, disclosed they increased the effective interest rate on this agreement by 4%. By itself, this suggests (or better said reconfirms) Niktimvo sales projections today are far higher than they were at the time they entered into the RPRX agreement in 11/2024. Be careful, we could be wrong (but doubt it). We have not listened to the call yet so perhaps the phenomenon was explained yesterday. If anyone can better explain please do so. $INCY $XBI $IBB
0 · Reply
Latest News on RPRX
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript

Feb 11, 2026, 4:44 PM EST - 4 weeks ago

Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript


Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 4 weeks ago

Royalty Pharma Reports Q4 and Full Year 2025 Results


Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Jan 12, 2026, 12:26 PM EST - 2 months ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

TEVA


Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 2 months ago

Royalty Pharma Announces Dividend Increase


Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 3 months ago

Royalty Pharma to Present at Upcoming Investor Conferences


Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 1:01 PM EST - 4 months ago

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript


Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 4 months ago

Royalty Pharma Reports Third Quarter 2025 Results


Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 5 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend


Royalty Pharma: Investor Day Upside

Sep 12, 2025, 3:54 PM EDT - 6 months ago

Royalty Pharma: Investor Day Upside


Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)

Sep 11, 2025, 8:16 PM EDT - 6 months ago

Royalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)


Royalty Pharma: Keep Delivering, Buy Confirmed

Aug 9, 2025, 6:23 AM EDT - 7 months ago

Royalty Pharma: Keep Delivering, Buy Confirmed


Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:52 PM EDT - 7 months ago

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript


Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Royalty Pharma Reports Second Quarter 2025 Results


Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 18, 2025, 8:15 AM EDT - 8 months ago

Royalty Pharma Declares Third Quarter 2025 Dividend


JuggernautRaider
JuggernautRaider Mar. 11 at 2:56 PM
$FBIO don’t be shocked if the sell the CUTX-101 royalty stream to $RPRX for a nice premium 🚀
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:34 PM
$RPRX Current Stock Price: $45.97 Contracts to trade: $45.0 RPRX Mar 20 2026 Call Entry: $1.20 Exit: $1.92 ROI: 60% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$RPRX Royalty Pharma Plc (NASDAQ: RPRX) is quietly becoming one of the most intriguing cheap biotech stocks as its royalty-based business model generates recurring revenue from blockbuster medicines. With analysts raising price targets and the company holding billions in financial firepower for new acquisitions, RPRX stock could offer investors exposure to biotech growth without the typical drug development risks. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-royalty-pharma-rprx-shares/
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 6 at 3:00 PM
$FBIO anyone else wondering if they’ll sell tbe CUTX-101 royalty stream to $RPRX ? 🧐
0 · Reply
TechridyStocks
TechridyStocks Mar. 6 at 1:39 AM
$RPRX still solid
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 2 at 1:39 PM
$RPRX (-7.2% pre) $ZYME (-3.3% pre) Ziihera cancer drug sparks $250M Royalty Pharma–Zymeworks deal https://ooc.bz/l/95120
0 · Reply
briefingcom
briefingcom Mar. 2 at 1:32 PM
$ZYME: Zymeworks & and Royalty Pharma $RPRX enter into $250 million royalty-backed note financing https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260302060706ZYME&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 12:15 PM
$RPRX Share Price: $46.22 Contract Selected: Oct 16, 2026 $52.5 Calls Buy Zone: $0.88 – $1.09 Target Zone: $1.55 – $1.90 Potential Upside: 67% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
StockNews_Live
StockNews_Live Mar. 2 at 11:10 AM
$RPRX Zymeworks Inc. (ZYME) announced a royalty-backed note financing of $250 million from Royalty Pharma plc (RPRX) with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid.…
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 28 at 2:05 AM
$SNDX SNDX did not record a "current portion of royalty financing agreement" on their 12/31/2025 Balance Sheet. The attachment summarizes the current & long-term obligations due RPRX as of the end of the last 5 quarters (per their Ks & Qs). The accounting for these royalty type agreements is complex. We are not CPAs but, generally speaking, the current portion represents amounts estimated due $RPRX over the following 12-months, allowing investors to determine SNDX calculated Niktimvo sales projections. SNDX, per their 10K, disclosed they increased the effective interest rate on this agreement by 4%. By itself, this suggests (or better said reconfirms) Niktimvo sales projections today are far higher than they were at the time they entered into the RPRX agreement in 11/2024. Be careful, we could be wrong (but doubt it). We have not listened to the call yet so perhaps the phenomenon was explained yesterday. If anyone can better explain please do so. $INCY $XBI $IBB
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:07 PM
$RPRX RSI: 83.57, MACD: 1.3636 Vol: 1.88, MA20: 43.08, MA50: 40.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
smartkarma
smartkarma Feb. 20 at 7:04 PM
$RPRX | Royalty Pharma’s Long Game—Synthetic Royalties, Portfolio Resilience, and Scalable Returns! "Royalty Pharma reported a strong set of results for the fourth quarter and full year 2025, reflecting continued momentum in portfolio receipts,..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/royalty-pharma-s-long-game-synthetic-royalties-portfolio-resilience-and-scalable-returns
0 · Reply
StockBraker
StockBraker Feb. 19 at 11:53 AM
$RPRX Mission accomplished
0 · Reply
d_risk
d_risk Feb. 11 at 11:35 PM
$RPRX - Royalty Pharma plc - 10K - Updated Risk Factors RPRX flags broader biopharma headwinds (trial failures, approvals, pricing, patents, safety) plus sharper leverage and liquidity constraints, higher concentration and competition for royalties, limited product visibility, expanded regulatory, IP, macro, and tax exposures, new key-person and organizational risks, and added legal, ESG, cybersecurity, and AI uncertainties. #PharmaceuticalRoyalties #OperationalRisk #MarketVolatility #FinancialLeverage #RegulatoryRisk #BiopharmaSector #ESGConcerns #IPChallenges #LiquidityConstraints #RegulatoryRisks 🟢 Added 🟠 Removed https://dev.d-risk.ai/RPRX/10-K/2026-02-11
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 11 at 12:44 PM
$RPRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.38 down -19.15% YoY • Reported revenue of $622M up 4.78% YoY • Royalty Pharma expects full year 2026 Portfolio Receipts to be between $3.28B and $3.43B, reflecting an expected Royalty Receipts growth of 3% to 8%.
0 · Reply
mikesterz7
mikesterz7 Feb. 11 at 12:41 PM
$RPRX 🚨 Adjusted Cash Flow (Non-GAAP): $1.46 per share. Total Revenue: $622 million (GAAP). Adjusted Revenue: $874 million. Net Income: $214 million. Earnings Beat: The reported adjusted EPS of $1.46 exceeded the consensus estimate of $1.33. Revenue Growth: The $622 million revenue marked a 4.7% increase from the $594 million reported in the same period last year. Full Year 2025 and Outlook Full Year 2025 Revenue: $3.25 billion. Full Year 2025 Net Income: $771 million. 2026 Outlook: The company projects full-year 2026 revenue in the range of $3.28 billion to $3.43 billion. Key Developments Dividend Increase: The company announced a 6.8% increase in its quarterly dividend to $0.235 per Class A share for Q1 2026. Deal Activity: The company experienced high deal velocity, announcing $4.7 billion in new transactions during 2025. Share Repurchases: In 2025, the company repurchased $1.2 billion in shares (35 million shares).
0 · Reply
JFDI
JFDI Feb. 10 at 4:46 PM
Clearly, alerts were not set. $RPRX
0 · Reply
victorgn
victorgn Feb. 6 at 6:31 PM
$RPRX 48.71 $ target
0 · Reply
StockBraker
StockBraker Feb. 4 at 8:36 PM
$RPRX New 52 week high reached today. Personally looking for $45.
0 · Reply
DappDelta
DappDelta Feb. 4 at 11:08 AM
$RPRX is a royalty-based pharma model providing non-correlated cash flows but is dependent on a few key blockbuster drugs.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 3 at 1:01 PM
$RPRX Share Price: $42.33 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $2.72 – $3.35 Target Zone: $4.68 – $5.73 Potential Upside: 63% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 3 at 4:07 AM
$RPRX Current Stock Price: $42.33 Contracts to trade: $42.5 RPRX Feb 20 2026 Call Entry: $0.80 Exit: $1.47 ROI: 83% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply